Tengteng Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tengteng Wang has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- A. Heather Eliassen
Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, USA
11 shared publications - Michelle D. Holmes
Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital, and Harvard Medical School , Boston, MA 02115
10 shared publications - Rulla M. Tamimi
Department of Population Health Sciences, Weill Cornell Medicine, New York, USA
10 shared publications - Walter Churchill Willett
Department of Nutrition, Harvard TH Chan School of Public Health, Harvard University , Boston, MA
10 shared publications Bernard A. Rosner
Channing Division of Network Medicine Brigham & Women's Hospital Boston Massachusetts USA
7 shared publications- Bernard Rosner
Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, USA
6 shared publications
Latest Publications
- Open Access
- 21 August 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (34)
A biomimetic, ultralow-power edge-AI-empowered and self-sustaining gait analysis system
Smart digital health has reshaped patient monitoring, but it faces a fundamental trade-off between device intelligence and continuous, energy-efficient monitoring. Inspired by self-sustaining intelligent biospecies, we develop a biomimetic, battery-free, and high-precision edge-AI system through a harvested-energy-constrained holistic co-design that couples ultralow-power edge-AI-empowered sensor hardware with biomechanical energy harvesting and cold-start power management. Our edge-AI-empowered motion sensor performs instantaneous, context-aware on-device inference and timely result updating from raw sensor data while consuming only 86 μW. A high-output energy harvester and tailored high-efficiency power management circuitry sustain energy levels exceeding system requirements, eliminating downtime associated with charging and enabling true 24/7, hassle-free monitoring. This breakthrough establishes a paradigm for system-level, edge-AI-empowered, and self-sustaining sensing, demonstrating that intelligence and energy autonomy can coexist within a single wearable platform and pointing to next-generation always-on, personalized digital health systems.
- 21 August 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (34)
Open AccessA biomimetic, ultralow-power edge-AI-empowered and self-sustaining gait analysis system
Smart digital health has reshaped patient monitoring, but it faces a fundamental trade-off between device intelligence and continuous, energy-efficient monitoring. Inspired by self-sustaining intelligent biospecies, we develop a biomimetic, battery-free, and high-precision edge-AI system through a harvested-energy-constrained holistic co-design that couples ultralow-power edge-AI-empowered sensor hardware with biomechanical energy harvesting and cold-start power management. Our edge-AI-empowered motion sensor performs instantaneous, context-aware on-device inference and timely result updating from raw sensor data while consuming only 86 μW. A high-output energy harvester and tailored high-efficiency power management circuitry sustain energy levels exceeding system requirements, eliminating downtime associated with charging and enabling true 24/7, hassle-free monitoring. This breakthrough establishes a paradigm for system-level, edge-AI-empowered, and self-sustaining sensing, demonstrating that intelligence and energy autonomy can coexist within a single wearable platform and pointing to next-generation always-on, personalized digital health systems.
- Open Access
- 17 December 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 91
Ultra-processed foods consumption and subsequent mortality in a cohort of Black breast cancer survivors
- 17 December 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 91
Open AccessUltra-processed foods consumption and subsequent mortality in a cohort of Black breast cancer survivors
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Loss of PTEN Expression, PIK3CA Mutations, and Breast Cancer Survival in the Nurses’ Health Studies
Supplementary Data from Loss of PTEN Expression, PIK3CA Mutations, and Breast Cancer Survival in the Nurses’ Health Studies
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Loss of PTEN Expression, PIK3CA Mutations, and Breast Cancer Survival in the Nurses’ Health Studies
Supplementary Data from Loss of PTEN Expression, PIK3CA Mutations, and Breast Cancer Survival in the Nurses’ Health Studies
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Loss of PTEN Expression, PIK3CA Mutations, and Breast Cancer Survival in the Nurses’ Health Studies
Background:The relationships between PTEN loss and/or PIK3CA mutation and breast cancer prognosis remain controversial. We aim to examine the associations in large epidemiologic cohorts.Methods:We followed women with invasive breast cancer from the Nurses’ Health Studies with available data on tumor PTEN expression (n = 4,111) and PIK3CA mutation (n = 2,930). PTEN expression was evaluated by IHC and digitally scored (0%–100%). Pyrosequencing of six hotspot mutations of PIK3CA was performed.Results:We found loss of PTEN expression (≤10%) occurred in 17% of cases, and PIK3CA mutations were detected in 11% of cases. After adjusting for clinical and lifestyle factors, PTEN loss was not associated with worse breast cancer-specific mortality among all samples [HR, 0.85; 95% confidence intervals (CI), 0.71–1.03] or among estrogen receptor (ER)-positive tumors (HR, 0.99; 95% CI, 0.79–1.24). However, among ER-negative tumors, PTEN loss was associated with lower breast cancer-specific mortality (HR, 0.68; 95% CI, 0.48–0.95). PIK3CA mutation was not strongly associated with breast cancer-specific mortality (HR, 0.89; 95% CI, 0.67–1.17). Compared with tumors without PTEN loss and without PIK3CA mutation, those with alterations (n = 540) were not at higher risk (HR, 1.07; 95% CI, 0.86–1.34). However, women with both PTEN loss and PIK3CA mutation (n = 38) were at an increased risk of breast cancer-specific mortality (HR, 1.65; 95% CI, 0.83–3.26).Conclusions:In this large epidemiologic study, the PTEN-mortality association was more pronounced for ER-negative tumors, and the joint PTEN loss and PIK3CA mutation may be associated with worse prognosis.Impact:Further studies with a larger sample of ER-negative tumors are needed to replicate our findings and elucidate underlying mechanisms.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Loss of PTEN Expression, PIK3CA Mutations, and Breast Cancer Survival in the Nurses’ Health Studies
Background:The relationships between PTEN loss and/or PIK3CA mutation and breast cancer prognosis remain controversial. We aim to examine the associations in large epidemiologic cohorts.Methods:We followed women with invasive breast cancer from the Nurses’ Health Studies with available data on tumor PTEN expression (n = 4,111) and PIK3CA mutation (n = 2,930). PTEN expression was evaluated by IHC and digitally scored (0%–100%). Pyrosequencing of six hotspot mutations of PIK3CA was performed.Results:We found loss of PTEN expression (≤10%) occurred in 17% of cases, and PIK3CA mutations were detected in 11% of cases. After adjusting for clinical and lifestyle factors, PTEN loss was not associated with worse breast cancer-specific mortality among all samples [HR, 0.85; 95% confidence intervals (CI), 0.71–1.03] or among estrogen receptor (ER)-positive tumors (HR, 0.99; 95% CI, 0.79–1.24). However, among ER-negative tumors, PTEN loss was associated with lower breast cancer-specific mortality (HR, 0.68; 95% CI, 0.48–0.95). PIK3CA mutation was not strongly associated with breast cancer-specific mortality (HR, 0.89; 95% CI, 0.67–1.17). Compared with tumors without PTEN loss and without PIK3CA mutation, those with alterations (n = 540) were not at higher risk (HR, 1.07; 95% CI, 0.86–1.34). However, women with both PTEN loss and PIK3CA mutation (n = 38) were at an increased risk of breast cancer-specific mortality (HR, 1.65; 95% CI, 0.83–3.26).Conclusions:In this large epidemiologic study, the PTEN-mortality association was more pronounced for ER-negative tumors, and the joint PTEN loss and PIK3CA mutation may be associated with worse prognosis.Impact:Further studies with a larger sample of ER-negative tumors are needed to replicate our findings and elucidate underlying mechanisms.
- Open Access
- 4 September 2025
- Published by Springer Nature in British Journal of Cancer
- Vol. 133 (9) , 1326-1334
Prospective study of circulating metabolomic profiles and breast cancer incidence among predominantly premenopausal women
Background: Associations between premenopausal plasma metabolites and breast cancer incidence are largely unknown. Methods: We conducted a prospective, matched case-control study in which we measured pre-diagnostic metabolomic profiles among predominantly premenopausal women in the Nurses’ Health Study II ( n = 2010). Lipids, carbohydrates, and organic acid-related metabolites ( n = 218) were profiled via liquid chromatography-tandem mass spectrometry. Conditional logistic regression was used to estimate odds ratios (OR) for associations between individual metabolites and breast cancer incidence. Associations with metabolite groups were assessed using metabolite set enrichment analysis (MSEA). Results: Six individual lipid-related metabolites were nominally associated with breast cancer incidence (taurodeoxycholate [OR for per 1 standard deviation increase in metabolite level = 1.15, 95% CI = 1.04–1.28]; C16:1 cholesteryl ester [OR = 0.88, 95% CI = 0.79–0.97]; three phosphocholine (PC)-related metabolites, C34:1 PC [OR = 0.87, 95% CI = 0.78–0.98], C34:3 PC [OR = 0.88, 95% CI = 0.79–0.98], C32:1 PC [OR = 0.88, 95% CI = 0.79–0.98]; indoxyl sulfate [OR = 0.90, 95% CI = 0.82–1.00]). In MSEA analyses, triglycerides (TAGs) with <3 double bonds (normalized enrichment score (NES) = −2.54) and PCs (NES = −2.12) were inversely associated with breast cancer incidence overall and across subgroups. Phosphatidylethanolamine (PE) plasmalogens (NES = 1.83) and PC plasmalogens (NES = 2.23) were positively associated with breast cancer incidence. Conclusions: Premenopausal plasma TAGs, PCs, and plasmalogen metabolites were associated with breast cancer incidence. Further validation in independent cohorts is warranted.
- 4 September 2025
- Published by Springer Nature in British Journal of Cancer
- Vol. 133 (9) , 1326-1334
Open AccessProspective study of circulating metabolomic profiles and breast cancer incidence among predominantly premenopausal women
Background: Associations between premenopausal plasma metabolites and breast cancer incidence are largely unknown. Methods: We conducted a prospective, matched case-control study in which we measured pre-diagnostic metabolomic profiles among predominantly premenopausal women in the Nurses’ Health Study II ( n = 2010). Lipids, carbohydrates, and organic acid-related metabolites ( n = 218) were profiled via liquid chromatography-tandem mass spectrometry. Conditional logistic regression was used to estimate odds ratios (OR) for associations between individual metabolites and breast cancer incidence. Associations with metabolite groups were assessed using metabolite set enrichment analysis (MSEA). Results: Six individual lipid-related metabolites were nominally associated with breast cancer incidence (taurodeoxycholate [OR for per 1 standard deviation increase in metabolite level = 1.15, 95% CI = 1.04–1.28]; C16:1 cholesteryl ester [OR = 0.88, 95% CI = 0.79–0.97]; three phosphocholine (PC)-related metabolites, C34:1 PC [OR = 0.87, 95% CI = 0.78–0.98], C34:3 PC [OR = 0.88, 95% CI = 0.79–0.98], C32:1 PC [OR = 0.88, 95% CI = 0.79–0.98]; indoxyl sulfate [OR = 0.90, 95% CI = 0.82–1.00]). In MSEA analyses, triglycerides (TAGs) with <3 double bonds (normalized enrichment score (NES) = −2.54) and PCs (NES = −2.12) were inversely associated with breast cancer incidence overall and across subgroups. Phosphatidylethanolamine (PE) plasmalogens (NES = 1.83) and PC plasmalogens (NES = 2.23) were positively associated with breast cancer incidence. Conclusions: Premenopausal plasma TAGs, PCs, and plasmalogen metabolites were associated with breast cancer incidence. Further validation in independent cohorts is warranted.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Reproducibility of Plasma Metabolome over 1 Year in a Population-Based Cohort of Black Breast Cancer Survivors
Supplementary Table S3 shows that differences in within-person reproducibility across participant characteristics and pre-analytical factors varied by metabolite class and subclass
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Reproducibility of Plasma Metabolome over 1 Year in a Population-Based Cohort of Black Breast Cancer Survivors
Supplementary Table S3 shows that differences in within-person reproducibility across participant characteristics and pre-analytical factors varied by metabolite class and subclass
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Data from Reproducibility of Plasma Metabolome over 1 Year in a Population-Based Cohort of Black Breast Cancer Survivors
Background:The metabolomics approach using blood samples from epidemiologic studies has the potential to elucidate pathways or uncover biomarkers for breast cancer outcomes. Therefore, understanding the within-person reproducibility of the blood metabolome and the factors that influence metabolite levels over time in breast cancer survivors are crucial, but these remain largely unknown.Methods:We estimated the within-person reproducibility of plasma metabolites in 61 Black breast cancer survivors from the Women’s Circle of Health Follow-Up Study. Samples were collected from each participant at two time points, approximately 2 and 3 years after diagnosis. Untargeted metabolomic profiles were analyzed by Metabolon using ultrahigh-performance LC/MS-MS. We calculated the intraclass correlation coefficients (ICC) for each metabolite by dividing the between-person variance by the total variance. ICCs were compared across preanalytic factors (e.g., fasting) and participant characteristics using the Wilcoxon test.Results:Among 857 named metabolites, the median ICC was 0.58 (IQR: 0.44–0.70). Of the metabolites, 16.6% showed high within-person reproducibility (ICC ≥ 0.75), spanning all metabolite classes, whereas 65.6% had an ICC within 0.4 to 0.75, and 17.9% had an ICC < 0.4. Reasonable ICCs were also observed for nonfasting samples (median 0.53, IQR: 0.39–0.67), although lower than those for fasting samples (median 0.63, IQR: 0.45–0.77). ICCs were slightly lower in younger, nonobese participants and in women with estrogen receptor–positive breast cancer.Conclusions:The within-person reproducibility of plasma metabolites over 1 year among breast cancer survivors was generally acceptable.Impact:A single-timepoint measurement could be useful in evaluating associations between metabolites and breast cancer outcomes.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Reproducibility of Plasma Metabolome over 1 Year in a Population-Based Cohort of Black Breast Cancer Survivors
Background:The metabolomics approach using blood samples from epidemiologic studies has the potential to elucidate pathways or uncover biomarkers for breast cancer outcomes. Therefore, understanding the within-person reproducibility of the blood metabolome and the factors that influence metabolite levels over time in breast cancer survivors are crucial, but these remain largely unknown.Methods:We estimated the within-person reproducibility of plasma metabolites in 61 Black breast cancer survivors from the Women’s Circle of Health Follow-Up Study. Samples were collected from each participant at two time points, approximately 2 and 3 years after diagnosis. Untargeted metabolomic profiles were analyzed by Metabolon using ultrahigh-performance LC/MS-MS. We calculated the intraclass correlation coefficients (ICC) for each metabolite by dividing the between-person variance by the total variance. ICCs were compared across preanalytic factors (e.g., fasting) and participant characteristics using the Wilcoxon test.Results:Among 857 named metabolites, the median ICC was 0.58 (IQR: 0.44–0.70). Of the metabolites, 16.6% showed high within-person reproducibility (ICC ≥ 0.75), spanning all metabolite classes, whereas 65.6% had an ICC within 0.4 to 0.75, and 17.9% had an ICC < 0.4. Reasonable ICCs were also observed for nonfasting samples (median 0.53, IQR: 0.39–0.67), although lower than those for fasting samples (median 0.63, IQR: 0.45–0.77). ICCs were slightly lower in younger, nonobese participants and in women with estrogen receptor–positive breast cancer.Conclusions:The within-person reproducibility of plasma metabolites over 1 year among breast cancer survivors was generally acceptable.Impact:A single-timepoint measurement could be useful in evaluating associations between metabolites and breast cancer outcomes.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Reproducibility of Plasma Metabolome over 1 Year in a Population-Based Cohort of Black Breast Cancer Survivors
Supplementary Table S1 presents the within-person reproducibility of all metabolites in the study population, calculated as the ICC
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Reproducibility of Plasma Metabolome over 1 Year in a Population-Based Cohort of Black Breast Cancer Survivors
Supplementary Table S1 presents the within-person reproducibility of all metabolites in the study population, calculated as the ICC
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Reproducibility of Plasma Metabolome over 1 Year in a Population-Based Cohort of Black Breast Cancer Survivors
Supplementary Table S4 highlights the specific metabolites that shifted from poor to excellent within-person reproducibility and vice versa across participant characteristics and pre-analytical factors
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Reproducibility of Plasma Metabolome over 1 Year in a Population-Based Cohort of Black Breast Cancer Survivors
Supplementary Table S4 highlights the specific metabolites that shifted from poor to excellent within-person reproducibility and vice versa across participant characteristics and pre-analytical factors
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Reproducibility of Plasma Metabolome over 1 Year in a Population-Based Cohort of Black Breast Cancer Survivors
Supplementary Table S2 identifies the metabolites with the lowest within-person reproducibility, defined as an ICC <0.4
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Reproducibility of Plasma Metabolome over 1 Year in a Population-Based Cohort of Black Breast Cancer Survivors
Supplementary Table S2 identifies the metabolites with the lowest within-person reproducibility, defined as an ICC <0.4